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A B S T R A C T
α-Terpineol (TP) is present in a wide range of essential oils of the genus Eucalyptus, with recognized potential for
a range of biological eﬀects, such as analgesic. Hence, our study aimed to investigate the eﬀect of TP on cancer
pain induced by sarcoma 180 in Swiss mice. Our results showed that TP reduced signiﬁcantly mechanical hy-
peralgesia and spontaneous and palpation-induced nociception, improved paw use without reducing tumor
growth and grip strength. Importantly, no evident biochemical and hematological toxicity was oberved.
Furthermore, TP increased the tissue antioxidant capacity due to ferric-reducing antioxidant power (FRAP) and
glutathione (GSH). TP also reduced inducible nitric oxide synthase (iNOS) immunocontent in the tumors.
Molecular docking estimated that TP binds within the same range of iNOS regions (other iNOS inhibitors), such
as N-Nitroarginine methyl ester (L-NAME). These data provide strong evidence that TP may be an interesting
candidate for the development of new safe analgesic drugs that are eﬀective for cancer pain control.
1. Introduction
The prevalence of cancer is increasing globally, with 17 million new
cases predicted for 2020, whereby pain is one of the most prevalent,
costly and distressing symptoms experienced by cancer patients [1].
Oncologic pain aﬀects 75–90% of patients with advanced disease stage
and can be considered as a signiﬁcant factor for life quality impairment
[2,3].
Oncologic pain presents a complex and multifactorial neurobiology.
The excessive proliferative status of cancer cells is considered as a
fundamental property of cancer [4]. Besides, the external micro-
environment that surrounds the cancer cells can also be altered by the
activation of the immune system, with the recruitment of macrophages,
neutrophils and T-cells and the consequent production of inﬂammatory
mediators [5]. Inﬂammation is often accompanied by increased re-
active species, revealing that the oxidative microenvironment sur-
rounding tumor cells is highly associated with increased oxidative
stress, either directly by cancer cells or indirectly by the activation of
the immune system [6].
Because of its pathophysiological complexity, up to 15% of nearly 7
million chronic pain patients can not be completely relieved by the
conventional management of this symptom. That occurs largely due to
the side eﬀects associated with the treatment such as constipation,
nausea, vomiting, sedation, respiratory depression, dependence, toler-
ance, bleeding, gastrointestinal ulceration, renal toxicity, hypotension,
cardiotoxicity, among others [5,6]. In this sense, a systematic review
has showed that medicinal plants have historically proved their ther-
apeutic potential and, today, still stand out as an important grouping
for the identiﬁcation of new analgesic drugs [7,8].
α-terpineol (TP) is an alcoholic monoterpene found in the essential
oil of several species belonging to the genus Eucalyptus [9]. This
monoterpene has peripheral-mediated antinociceptive eﬀect due to its
ability to inhibit the cyclooxygenase enzyme and the production of
inﬂammatory mediators and cytokines such as prostaglandin E2
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(PGE2), interleukin-1β (IL-1β) and nuclear factor kappa B (NF-kB)
[10–15]. This substance also modulates the levels of nitric oxide (NO),
an important marker of oxidative stress [16]. However, studies that
show the eﬀect of TP on chronic pain, such as cancer pain, are scarce.
Considering the need for new therapeutic options for oncologic pain
and the therapeutic potential of monoterpenes, especially TP, this study
aimed to evaluate the eﬀect of TP on nociceptive responses induced by
sarcoma 180 (S180) in rodents.
2. Methods
2.1. Chemicals
α-Terpineol (96% purity), cremophor, sodium chloride, tripan blue,
nitrobenzoic acid, glycerol, β-mercaptoethanol, bromophenol blue,
tween, thiobarbituric acid, Tetraethoxypropane (TEP), tripyridyl-
triazine (TPTZ), dinitrobenzoic acid (DTNB) and glutathione (GSH)
were purchased from Sigma (USA). Morphine and lactated ringer's so-
lution were purchased from Cristália (São Paulo, São Paulo, Brazil).
Ketamine and Xylazine were purchased from Cristália (Itabira-SP,
Brazil). Acetic acid, hematoxylin and eosin were purchased from Synth
and EDTA from Neon. Protease inhibitors were derived from Sigma
(FAST), primary anti-iNOS and anti-β-actin antibodies (Santa Cruz
Biotechnology Inc - Santa Cruz, CA, USA). Anti-rabbit IgG-HRP and IgG-
HRP anti-mouse secondary antibodies were purchased from Sigma (St.
Louis, MO).
2.2. Animals
Male Swiss mice used (28–32 g; 2–3 months of age) were randomly
housed in appropriate cages at 22 ± 2 °C on a 12 h light/dark cycle
with free access to food (Purina®, Brazil) and water. Experimental
protocols were approved by the Animal Care and Use Committee
(CEPA/UFS 05/14) at the Universidade Federal de Sergipe, and all
handling procedures were in accordance with the International
Association for the Study of Pain (IASP) guidelines for the use of ani-
mals in pain research.
2.3. Tumor cell and implantation
S180 tumor cells that had been maintained in the peritoneal cavity
of Swiss mice were obtained from the Laboratory of Clinical and
Experimental Oncology at the Federal University of Sergipe. A sus-
pension of 106 viable S180 cells per 25 μl of lactated Ringer’s solution
was implanted subcutaneously into the plantar region of mice. Animals
of the sham group received only 25 μl of lactated Ringer’s solution
[17,18].
2.4. Treatment
Twenty-four hours after administration of S180, animals (n= 08/
group) were treated daily with vehicle (saline+ cremophor 0.4% v/v),
TP (12.5, 25 or 50mg/kg) or morphine (15mg/kg) via subcutaneous
route until the ﬁfteenth day and were then submitted to behavioral
evaluation on alternate days. The route of administration of the treat-
ments was subcutaneous so that the hepatic ﬁrst-pass eﬀect was
avoided. The animals were randomly distributed between the groups
and the evaluations were performed blindly in order to reduce the as-
sessment bias.
2.5. Behavioral studies
The mechanical hyperalgesia was assessed by means of digital von
Frey (Model: EFF-301, Insight®, Brazil) through hind paw ﬂexion reﬂex,
which corresponds to the paw withdrawal followed by clear ﬂinching
movements. In order to evaluate the spontaneous nociception, mice
were placed scattered in boxes and allowed to acclimate for 10min.
Afterwards, the ﬂinching behaviors were observated during a 10-min
period. Non-noxious palpation of the tumor-bearing paw was per-
formed during 2min and the number of ﬂinching behaviors was
quantiﬁed for 2min to determine the palpation-induced nociception
[19]. The use of the limb was evaluated as previously described by
Luger et al. [20], through the observation of the mouse while walking
in a continuous movement. The limb and/or guard behavior of the right
hind limb (treated with sarcoma) was evaluated in the following scale:
0 = complete lack of use, 1 = partial limb use in locomotor activity, 2
= limb and guard behavior, 3 = substantial limping and 4 = normal
walking [20].
2.6. Measurement of forelimb grip strength
In order to check for possible changes in neuromuscular function,
such as the myorrelaxant eﬀect, we measured the tension force of limbs
using the commercial grip strength meter (Insight®, Brazil) before the
treatment (s.c.) of tumor-free animals with vehicle or TP (12.5, 25 or
50mg/kg) and 30, 60 and 120min after treatment [21].
2.7. Measurement of paw volume
The eﬀect of TP on tumor growth of S180 was evaluated through
right paw volume, which was measured using plethysmometer
(Insight®, Brazil) before (time zero) and on every other day up to 15
days.
2.8. Toxicity
Toxicity assessment was performed by means of the weight control
of the animals and behavioral changes prior to tumor inoculation daily
until the 15th day of the experiment. On the last day, the biochemical
and hematological analyses were performed to evaluate glutamic-ox-
alacetic transaminase, glutamic-pyruvic transaminase, urea, creatinine,
the total and diﬀerential leukocyte count, red blood cells, hemoglobin,
hematocrit and platelets. The weights of vital organs such as heart,
lung, brain, liver and kidneys were checked after the euthanasia of the
mice, which were macroscopically observed. The relative weight of the
organs was calculated as follows: Relative weight = [(body weight/
body weight) x 100]. After that, the organs were submitted to histo-
pathological analysis after staining with hematoxylin and eosin. Finally,
the slides were analyzed in an optical microscope and documented in a
photo microscope (Olympus®) using standard and polarized polychro-
matic light.
2.9. Histology
Diﬀerent groups of animals were euthanized with excessive sedation
on the 15th day after sarcoma inoculation. The paws were then sub-
mitted to ﬁxation with 10% formalin solution, decalciﬁed in 10% EDTA
(pH 7.4) for two weeks and submitted to conventional histological
processing. Sections were cut in the sagittal plane and stained with
hematoxylin and eosin for optical microscopic visualization of the
histopathological characteristics of the tumor [22].
2.10. Antioxidant capacity of tissues
On the 15th day, tumor, spinal cord and brain were homogenized
using turrax-type homogenizer in ice bath and 0.1M potassium phos-
phate buﬀer pH 7.0. The homogenate was centrifuged at 15,000 rpm for
30min at 4 °C. The supernatant was used for the determination of re-
ducing power (FRAP), glutathione (GSH) and thiobarbituric acid re-
active substances (TBARS).
For the FRAP assay, in a 96-well plate, a 9-μl aliquot of the homo-
genate was mixed with 27 μL of distilled water and 270 μL of the FRAP
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fresh reagent and incubated at 37 °C [23]. After 30min, the absorbance
was read at 595 nmA ferrous sulfate curve was prepared under the
same conditions and results were expressed in mM ferrous sulfate/ mg
tumor protein, spinal cord and brain.
For GSH, the homogenates were resuspended in a solution of EDTA
(10-3M) in 5% TCA [24]. Subsequently, they were centrifuged at
15,000g for 15min at 4 °C and the supernatant was collected. For the
assessment, 275 μl of phosphate buﬀer pH 8.0 and 20 μl of the GSH-
containing supernatant were placed in a 96-well plate. Then, 10 μl of
DTNB (5mM, dissolved in ethanol) was added and after 5min, the
absorbance was read at 412 nm. The GSH concentration was quantiﬁed
using a standard GSH curve. The results were expressed in mM GSH/g
tumor protein, spinal cord and brain.
The assessment of TBARS was performed by the method of Ohkawa,
Ohishi and Yagi [52] with some modiﬁcations: in tubes, there was the
addition of 100 μL of homogenate, 350 μL of 20% acetic acid (pH 3.5)
and 600 μL of thiobarbituric acid (TBA 0.5%, dissolved in acetic acid).
The tubes were incubated in a thermostated bath for 1 h at 85 °C. They
were then cooled in an ice bath and centrifuged at 10,000 rpm for
15min at 4 °C and the absorbance was measured at 532 nmA tetra-
epoxypropane (TEP) curve was made and the results were expressed in
μM of TEP/g tumor protein.
2.11. Western blot
Immunoblotting was performed as previously described. Forty mi-
crograms of protein was fractionated by SDS-PAGE and transferred to
nitrocellulose membranes with 0.45-μm pore (Bio-Rad, CA, USA).
Protein loading and trasferred eﬃciency were veriﬁed though Ponceau
S staining. The membranes were washed with TTBS (100mM Tris-HCL,
pH 7.5, containing 0.9% NaCl and 0.1% Tween-20) and then were
blocked for 2 h in Tris-buﬀered saline-Tween 20 containing 5% non-fat
dry milk at room temperature After, the membranes were incubated
overnight at 4 °C with rabbit polyclonal and monoclonal antibodies
anti-β.actin (1:300, sc-32233) and anti-iNOS (sc-8310), from Santa
Cruz biotechnology. After that, they were washed and incubated for 2 h
at room temperature with peroxidase-conjugated secondary antibody
(1:2000, anti-rabbit and anti-mouse IgG-HRP, Sigma, MO, USA).
Immunodetection was performed using enhanced chemiluminescence
(Luminata strong™ - Western HRP substrate, Merck-Millipore, MA,
USA). Digitalized images were analyzed through densitometry using the
ImageJ 1.40 software (NIH).
2.12. Docking studies
The structure of the Nitric Oxide Synthase enzyme (ID PDB 1m7z)
was downloaded from Protein Data Bank (http://www.rcsb.org/pdb/
home/home.do). Using the Hyperchem v. 8.0.3, the chemical structure
of the binders was designed: TP, aminoguanidine, dexamethasone, N-
nitro-L-arginine methyl ester (L-NAME) and their geometry was opti-
mized using MM+ force ﬁeld.
Following, a new optimization of the geometry based on the semi-
empirical method AM1 (Austin Model 1) was performed. The optimized
framework underwent conformational analysis using the Spartan soft-
ware for Windows 10.0. The random search method was selected with
1000 interactions, 100 optimization cycles and 10minimum low-en-
ergy shapers. The dihedrons were evaluated through rotation according
to the standard (absence) conditions of the program, in which the
number of simultaneous variations was from 1 to 8, the acyclic chains
were rotated from 60 to 180ø and the torsion rings were in the range of
30 to 120 °C.
The ligands underwent molecular anchoring using the Molegro
Virtual Docker v. 6.0.1 (MVD). All water compounds were eliminated
from the receivers and the method was prepared using predeﬁned
parameters in the same software: 15 Âμ radius GRID. Moldock score
[GRID] algorithm was used as the score function and the search
algorithm was Moldock.
2.13. Statistical analysis
The data obtained were evaluated by means of one- and two-way
analyses of variance (ANOVA) followed by Bonferroni´s or Tukey´s test.
Kruskal–Wallis followed by Dunn's test was applied to limb use. In all
cases, diﬀerences were considered signiﬁcant if p < 0.05, using the
Graph Pad Prism (v 5.00) software (San Diego, CA, USA). The percent
of inhibition was determined using the following formula: Inhibition%
(PI)= 100 (control− experiment) / control, with the data obtained
from the area under the curve (AUC).
3. Results and discussion
In this study, TP was able to attenuate the nociception induced by
the inoculation of S180 cells into the paw of mice. For so, diﬀerent
methods of evaluation were used that imitate the diﬀerent modalities of
pain experienced by cancer patients. The ﬁrst one was hyperalgesia,
which indicates increased sensitivity to painful stimuli with the in-
volvement of C and A-δ ﬁbers [25]. In our study, S180 cells promoted a
signiﬁcant increase of this hyperalgesia in vehicle-treated animals
compared to animals of the sham group (p < 0.001) on the 9th day, as
observed in previous studies [17,18].
The treatment of the animals with TP in doses of 12.5 and 25mg/kg
was able to reduce signiﬁcantly (p < 0.05 on day 9, p < 0.01 on day
11 and< 0.001 on days 13 and 15 in both doses) mechanical hyper-
algesia from the 9th to the 15th day after administration of the tumor
cells, with percentages of inhibition of 24.72% and 30.63%, respec-
tively. TP at 50mg/kg also reduced hyperalgesia (p < 0.01 on day 9
and p < 0.001 as of day 11) when compared to vehicle-treated ani-
mals, with a percentage of inhibition of 35.17%. Morphine (15mg/kg)
also promoted the relief of the hyperalgesic response (p < 0.001) from
the 9th to 15th day of tumor induction, with 76.34% inhibition
(Fig. 1A). In other studies, TP also triggered an antihyperalgesic eﬀect
on chronic muscular pain, probably evoked by the modulation of the
opioid and serotonergic (5HT3) systems and pain models induced by
carrageenan, TNF-α, PGE2 and dopamine, with reduction of leukocytes
and production of nitric oxide [14,26]. In fact, the modulation of these
systems has been the treatment strategy to reduce cancer pain curren-
tily worldwide [27].
Besides hiperalgesia, we also evaluated the spontaneous nocicep-
tion, a behavioral response associated with sensitization of C-ﬁber no-
ciceptors and studied in several pain models [28]. Animals treated with
the vehicle had an increase in the number of ﬂinches when compared to
animals of the sham group (p < 0.05 on day 9, p < 0.001 on day 11
to 15). TP 12.5 (p < 0.05 on day 15) and TP 25 (p < 0.01 at day 15)
and TP 50mg/kg (p < 0.05 on day 9, p < 0.001 from day 11) were
able to signiﬁcantly reduce the number of spontaneous nociceptive
responses (ﬂinches), with percentage inhibition of 38.24; 50.71 and
99.65%, respectively. Treatment with TP 50mg/kg presented inhibi-
tion similar to morphine (99.32%) (Fig. 1B).
In order to mimic allodynia, we measured the nociception evoked
by palpation in animals with cancer, which is deﬁned as pain in re-
sponse to a non-nociceptive stimulus induced by low-threshold ﬁbers,
such as A-β ﬁbers [25]. In this study, the intraplantar injection of S180
cells promoted a signiﬁcant increase in the number of ﬂinches after
palpation. As shown in the Figure (Fig. 1C), TP was able to decrease the
number of ﬂinches when compared to the vehicle (p < 0.05 on day 9,
p < 0.01 on day 11 and p < 0.001 on the 13th and 15th day). The
reduction of noception induced by non-nocive palpation was observed
in mice treated with TP 12.5 mg/kg (p < 0.05 at day 15), TP 25mg/kg
(p < 0.001 on the 15th day) and TP 50mg/kg (p < 0.05 on day 9,
p < 0.01 on day 11 and p < 0.001 on days 13 and 15) when com-
pared to vehicle group. These doses presented inhibition percentages of
16.62, 30, 57 and 95.54%, respectively. There was no signiﬁcant
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diﬀerence between the group treated with TP 50mg/kg and the group
that received morphine as treatment, which reduced the allodynia in
97.45% (Fig. 1C).
In the tumor environment, cancer and immunological cells release
several inﬂammatory mediators and cell factors that sensitize A and C
ﬁbers, promoting changes in nervous transmission and leading to the
perception of diﬀerent types of pain, including hyperalgesia and allo-
dynia [5]. In our study, TP reduces all nociceptive responses, reinfor-
cing its antinociceptive activity. This compound may reduce the pain
thanks to central or peripheral mechanisms, as demonstrated in a study
published by Quintans-Júnior et al. [15]. In fact, several studies have
showed TP modulation of neurotrasmissors [14,26], ion channels [29],
decrease in pro-inﬂammatory cytokines as TNF-α [30], IL-6 [11], IL-1β
[31], increase in IL-10, an important anti-inﬂammatory cytokine, and
inhibitors of the expression of COX-2 and iNOS [32], via NF-kB and ERK
pathways [31,32].
The tumor also caused impairment of limb use evidenced by
changes in normal ambulation in animals treated with vehicle com-
pared to the sham group (p < 0.01 on days 9 and 11, p < 0.001 at 13
and 15). The treatments with TP 50mg/kg (p < 0.01 at day 9 and day
11, p < 0.001 at day 13 and p < 0.05 at day 15) and with morphine
(p < 0.01 at day 9 and day 13, p < 0.05 at 11 and 15 days) atte-
nuated the eﬀects induced by sarcoma 180 (Fig. 2A). Animals treated
with vehicle increased paw volume when compared to the non-tumor
sham group (p < 0.01 on the 9th day and p < 0.001 as of the 11th
day). TP was not able to reduce the tumor growth (Fig. 2B), showing
that the antinociceptive and antihyperalgesic activity of TP does not
depend on the decrease of the tumor mass. In previous studies, TP
Fig. 1. Eﬀect of α-terpineol (TP, 12.5–50mg/kg, s.c.) on the mechanical hyperalgesia (A), spontaneous (B) and palpation-induced nociception (C) in mice with S180
(n=8/group). *p < 0.05, **p < 0.01 and ***p < 0.001 vs. the control group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. morphine (one-way ANOVA fol-
lowed by Tukey's test).
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reduced the growth of epithelial malignancies and, in an in vitro study,
inhibited the growth of tumor cells from blood samples of patients with
chronic lymphocytic leukemia [10,33].
Tumor presents an oxidative environment with extracellular release
of glutamate, which is responsible for stimulating nerve transmission,
causing painful conditions in humans [34,35]. For this reason, the
present study also aimed to evaluate the eﬀect of TP on the oxidative
stress induced by S180, through the evaluation of the antioxidant ca-
pacity in the tumor, brain and spinal cord using the oxidative stress
markers FRAP, GSH and TBARS.
In order to evaluate the inﬂuence of the tumor and the treatment
with TP 50mg/kg on the oxidative stress, the antioxidant capacity of
the tissues was evaluated by the FRAP method. Treatment with TP
(50mg/kg) increased the concentration of substances capable of redu-
cing iron in the tumor when compared to groups receiving vehicle
(p < 0.01) and morphine (p < 0.01) as treatment. This evaluation
was not performed with the sham group due to the absence of tumor
mass in the animals belonging to this group (Fig. 3A). Similarly, the
brain homogenate of animals treated with TP (50mg/kg) also increased
the tissue-reducing ability (p < 0.05) when compared to vehicle
(Fig. 3B). In contrast, the spinal cord homogenate of animals treated
with TP did not show signiﬁcant diﬀerences (Fig. 3C) in FRAP when
compared to the vehicle and morphine groups, although it has showed a
tendency to do so. Thus, the reducing capacity of TP, highlighted in
FRAP, can contribute to the decrease in pain, once reactive species have
an important role in the development of peripheral and central sensi-
tization of the various pain etiologies [36]; also, the oxidation also
sensitizes peripheral nociceptors by increasing the excitability of vol-
tage-operated sodium channels [37].
In order to assess tissue redox status, the GSH concentration was
determined. Increased GSH concentration was observed in the tumor
homogenate (p < 0.001 versus vehicle; p < 0.001 versus morphine)
and the brains (p < 0.05 versus vehicle) belonging to the TP-treated
group, as shown in Fig. 4A and B, respectively. The homogenates ob-
tained from the spinal cord of animals treated with TP did not present
signiﬁcant diﬀerences in GSH concentrations when compared with the
vehicle and morphine groups (Fig. 4C). These ﬁndings suggest that TP
reduces the oxidative stress induced by S180 by preserving GSH levels,
preventing the depletion of total antioxidant capacity and oxidative
stress, as well as contributing to the reduction of nociceptive responses
induced by tumor cells.
Similar results have been observed for other natural products, such
as quercetin, which is able to reduce cancer pain with the molulation of
GSH levels, indicating that the prevention of GSH depletion may be an
Fig. 2. Eﬀect of terpineol (TP, 12.5–50mg/kg, s.c.) on the paw use (A) and the tumor growth (B) in mice with S180 (n= 8/group). *p < 0.05, **p < 0.01 and
***p < 0.001 vs. the control group (Paw use: median with interquartile range, Kruskal–Wallis followed by Dunn's test. Paw volume: mean ± SEM, two-way ANOVA
followed by Bonferroni's test).
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important analgesic mechanism, as it has been demonstrated [38].
Besides, a recent study shows that the administration of GSH sup-
pressed mechanical allodynia and central sensitization in rats with
chronic post-ischemia pain [39]. It is worth noting that rises in GSH
levels seem to be more expressive in the tumor and in the brain. On the
other hand, changes in glutamate neurotransmission at medullary le-
vels have been most strongly associated with the redox imbalance as-
sociated with the tumor [6].
However, no signiﬁcant diﬀerences were found between groups
tested for TBARS concentrations in the tumor, an important marker of
lipid damage in oxidative stress (Figure S2). That diﬀers from the
ﬁnding in another study, which shows that TP suppresses lipid perox-
idation in the hippocampus, improving cerebral ischemia-related
memory impairment in rats [40]. This contradiction can be associated
to tissue characteristics, once that the brain is rich in lipids, being a
target of peroxitarion [41], diﬀerent from the tumor evaluated.
It is well known that the redox status also inﬂuences threshold NO
levels within the tumor microenvironment [42]. Indeed, nitric oxide
(NO) may act as an important neurotransmitter aﬀecting spinal noci-
ceptive processing in several pain models [43,44]. The isoform iNOS
stands apart as it generates more NO than do the constitutive members,
expressed after cytokine exposure and involved in the development and
maintenance of central and peripheral sensitization in inﬂammatory
and neuropathic pain [45,46]. Several studies have provided consistent
evidence that iNOS levels within tumor microenvironment plays a pi-
votal role in the maintenance of cancer pain [42,43] due to nociceptive
sensitization. In accordance, we demonstrated that TP was able to at-
tenuate of immunocontent of iNOS (p < 0.01) induced by tumor-
bearing S180 when compared with vehicle group (Fig. 5).
Besides, molecular docking was performed in order to verify the
energy of complex formation of the enzyme nitric oxide synthase to-
gether with TP and with inhibitors of this enzyme, such as L-NAME,
aminoguanidine and dexamethasone (Fig. 6). TP presented a hydrogen
bond (blue lines) and a steric binding with THR324 (red lines), with
energy binding close to the energy presented by dexamethasone and L-
NAME and lower than the energy of aminoguanidine. Dexamethasone
showed three hydrogen bonds: two with the residue THR324 and one
with ARG243. In addition, there were steric bonds between apolar
atoms with ARG243, THR324 and TRP325. L-NAME presented three
hydrogen bonds: with ARG243, THR324 and TRP325 (blue lines) of the
enzyme NOS and steric connections with residues ARG243, TRP325,
MET236 and PRO329 (red lines). Aminoguanidine showed two hy-
drogen bonds with the TRP234 residue. In fact, a previous study de-
monstrated that TP can modulate the nitric oxide pathway, attenuating
the dependence and tolerance to morphine by NO production, an eﬀect
that was potentiated by L-NAME and antagonized by L-arginia [47].
The modulation of the production of reactive oxygen species seems
to be an important target to control pain, since compounds with sca-
venger eﬀects have showed suppressed action of mechanical allodynia
in a rat model of cancer-induced bone pain [48]. In fact, nitric oxid
produced by iNOS enzyme in pathologic conditions activates TRPV1
and TRPA1 channels promoting nociception in mice [44] and causing
central pain sensitization [49].
During the 15 days of experiment, an increase was observed in the
weight of the animals treated with TP 12.5 mg/kg (p < 0.01 on the
12th and 15th days; p < 0.05 on the 14th day) and TP 50mg/kg
Fig. 3. Inﬂuence of TP on the antioxidant capacity (FRAP method) of tumors (A), brain (B) and spinal cords (C) in mice containing S180. * p < 0.05, ** p < 0.01
versus vehicle group and ##p < 0.01 versus morphine group (one-way ANOVA followed by Tukey's post-test).
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(p < 0.05 on the 9th, 12th and 13th days, p < 0.01 on the 10th and
14th days), when compared to the vehicle-treated group (Figure S3).
This weight gain may be related to the animal welfare in relation to the
treatment with TP, once that according to OECD [53], a signiﬁcant
body weight loss can be an indicator of deteriorating animal condition.
Although we did not notice apparent changes in feed consumption,
other studies can assess the feeding behavior through the evaluation of
the feed consumption for a better understanding of this eﬀect. In ad-
dition, no behavioral changes suggestive of TP toxicity were evidenced.
No changes suggestive of toxicity were observed in the hematological
and biochemical parameters (Table S1), in the necropsy of the animal
organs and histopathological analysis of the liver and kidneys (Figure
S3). These ﬁndings corroborate Api et al. who in a short review sum-
marized several evidences about the safety of terpineol [50].
In contrast, all animals treated with morphine presented reducing
palpebral and auricular reﬂexes, as well as reaction of Straub's tail, a
central excitatory eﬀect of this drug caused by the contraction of the
dorsal sacrococcygeus muscle [51]. Animals treated with morphine had
a signiﬁcant weight reduction (p < 0.05 on the 13 and 15th days and
p < 0.01 on the 14th days) when compared with those from the ve-
hicle group (Figure S3). It was veriﬁed that the animals with the tumor
treated with morphine presented increase (p < 0.01) in the weight of
the encephalous when compared with the animals of the vehicle group.
This increase was not observed in the animals of the other groups,
which presented values close to the animals without the tumor (Table
S2).
However, animals treated with morphine showed an increase in
brain size when compared to the vehicle group. The
Fig. 4. Eﬀect of chronic administration of TP
on the GSH concentrations in mM per gram of
homogenate of tumors (A), brain (B) and spinal
cords (C) in mice containing S180 (n=5/
group). * p < 0.05, *** p < 0.001 versus
vehicle group and ### p < 0.001 versus
morphine group (one-way ANOVA followed by
Tukey post-test).
Fig. 5. Eﬀect of TP on the tumor-bearing S180 induced by iNOS immunocontent in the paw. Representative western blot and densitometric analyses. Data are
expressed as the mean ± SEM, n= 5 animals/group. ** p < 0.01 versus the vehicle group (one-way ANOVA followed by the Dunnett’s post-test).
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anatomopathological analysis of this organ showed no degeneration or
cellular alteration of the tissues, what suggests that the administration
of morphine did not cause functional toxic damage to the encephalon
(Figure S5). The structures of the encephalous of the other groups were
also preserved, with no apparent changes in the cortical, hippocampal
and cerebellum regions. Finally, we observed that mice treated with
vehicle had a reduction of muscle strength when compared to the an-
imals of the sham group (p < 0.001 on the 13th and 15th days). TP did
not promote changes in grip strength (Fig S1), corroborarting Oliveira
et al. [26], who show TP did not develop alterations in motor co-
ordination in Rota rod test. Therefore, the antihyperalgesic eﬀect of TP
observed in this study is not entirely due to muscle relaxation or an
inhibitory CNS eﬀect.
In conclusion, the present study demonstrates that TP reduces the
nociception induced by sarcoma 180 in rodents, without promoting
myorelaxant eﬀect. This antinociceptive eﬀect of TP probably occurs
thanks to the mechanisms related to the modulation of oxidative stress,
with maintenance of the endogenous antioxidant substances and re-
duction of iNOS levels. This study also suggests that chronic adminis-
tration of TP does not trigger evidence of preclinical toxicity. The an-
algesic dose of TP did not alter tumor growth, demonstrating that its
analgesia does not depend on the reduction of tumor mass.
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Fig. 6. Complex formation energy (ligand+ receptor) and binder maps to Nitric Oxide Synthase – α-terpineol (A), Nitric Oxide Synthase – Dexamethasone (B), Nitric
Oxide Synthase - L-NAME (C), and Nitric Oxide Synthase – Aminoguanidine (D). Blue lines - Hydrogen bonds and red lines - Steric interactions.
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Figure S1. Effect of chronic administration of TP on tetraepoxypropane (TEP) 4 
concentrations. The results were expressed in μM TEQ Eq per gram of S180 tumor (n = 5 
5/group) (one-way ANOVA followed by Tukey's post-test). 6 
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Figure S2. Weight evolution of sham animals and those treated with vehicle, TP and 9 
morphine for 15 days (n = 8/group). * p < 0.05 and ** p < 0.01 versus the control group 10 
(two-way ANOVA followed by the Bonferroni post-test). 11 
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Figure S3. Histological analysis of the Kidney and liver sections stained-H&E (40x 23 
objective), showing respectively conserved glomeruli (g), distal tubule (dt) and 24 
proximal tubule (pt), such as well-preserved liver plates (p) and hepatic portal vein (*). 25 
Liver presented normal-looking hepatic parenchyma, preserved lobes, central vein, 26 
hepatocyte cords and triad portal, without the presence of inflammatory infiltrate, 27 
fibrosis or hemorrhagic spots on the hepatic lobe. The cortical and medullary regions of 28 
kidneys were normal, with glomeruli, renal tubules and preserved capillaries.  29 
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 32 
Figure S4. Photomicrographs (250 μm) of the cerebral cortex, hippocampus and 33 
cerebellum of sham animals, vehicle, TP 50 mg/kg and morphine, 15 days after tumor 34 
induction and daily treatment. 35 
 36 
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Figure S5. Effect of terpineol (TP, 12.5 to 50 mg/kg, s.c.) on the strength intensity im 38 
mice with S180 (n= 8/group). ***p < 0.001 vs. the control group (ANOVA two-way 39 
followed by Bonferroni's test) 40 
 41 
 42 
 43 
 44 
4 
 
Table S1. Hematological and Biochemical analysis of euthanized animals after 15 days 45 
of TP administration (mean ± SEM). 46 
Hematologic 
parameters 
Sham Vehicle TP (50 mg/kg) Morphine 
Blood Cells 
(10
6
/mL) 
7.49 ± 0.65 8.69 ± 0.31 8.50 ± 0.33 7.77 ± 0.45 
Hemoglobin 
(g/dL) 
12.68 ± 1.12 13.74 ± 0.44 13.71 ± 0.59 13.08 ± 0.67 
Hematocrit (%) 42.33 ± 3.21 47.47 ± 1.99 46.91 ± 2.33 42.25 ± 2.13 
Total leukocytes 
(10
3
/mL) 
5.88 ± 1.12 6.25 ± 0.92 9.01 ± 2.06 5.32 ± 0.77 
Neutrophils (%) 40.58 ± 5.32 39.33 ± 2.88 41.20 ± 1.78 36.00 ± 5.95 
Eosinophil (%) 1.40 ± 1.23 0.53 ± 0.14 0.18 ± 0.05 0.72 ± 0.49 
Monocytes (%) 1.80 ± 0.69 6.59 ± 0.99 5.50 ± 1.09 1.42 ± 0.39 
Lymphocytes (%) 55.88 ± 6.21 50.34 ± 3.80 52.66 ± 1.70 61.62 ± 5.78 
Platelets 
(10
3
/mL) 
1187.25 ± 
208.20 
1014.33 ± 
52.58 
1174.00 ±  
117.94 
1335.83 ± 
115.28 
 47 
Biochemical 
parameters 
Sham Vehicle TP (50 mg/kg) Morphine 
TGO (U/L) 178.90 ± 17.55 225.83 ± 17.55 224.50 ± 23.63 
210.13 ± 
12.47 
TGP (U/L) 56.90 ± 6.22 71.25 ± 9.41 53.08 ± 11.22 49.63 ± 4.22 
Urea (mg/dL) 47.60 ± 2.12 46.83 ± 2.4 43.33 ± 2.50 49.13 ± 2.42 
Creatinine 
(mg/dL) 0.35 ± 0.02 0.42 ± 0.02 0.40 ± 0.03 0.34 ± 0.01 
 48 
Table S2. Analysis of body weight. * p < 0.05 versus vehicle group (mean ± SEM). 49 
Organs 
(mg/100 mg 
body weight) 
Sham Vehicle TP (50 mg/kg) Morphine 
Brain 1.44 ± 0.06 1.25 ± 0.04 1.48 ± 0.02 1.63 ± 0.03* 
Heart 0.51 ± 0.03 0.50 ± 0.02 0.48 ± 0.12 0.51 ± 0.01 
Lung 0.52 ± 0.13 0.53 ± 0.03 0.54 ± 0.013 0.64 ± 0.02 
Liver 6.64 ± 0.33 5.87 ± 0.16 5.92 ± 0.26 6.21 ± 0.18 
Kidney 1.51 ± 0.19 1.34 ± 0.23 1.63 ± 0.06 1.82 ± 0.14 
 50 
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